BillionToOne, Inc. (BLLN) Company Overview

BillionToOne, Inc. is a molecular diagnostics company listed on the Nasdaq Global Select Market under BLLN. The company went public on November 6, 2025 at an initial offering price of $60 per share, according to its official investor FAQ. Its core proposition is unusually specific: measure very small amounts of disease-related DNA in a blood sample with single-molecule sensitivity, then turn that measurement into clinically useful prenatal or oncology information.

Why does the technology matter clinically?

Conventional sequencing can struggle when the clinically important signal is rare relative to normal background DNA. BillionToOne’s technology description explains an add-amplify-count-compute workflow that uses QCTs to estimate the original number of target molecules. In prenatal testing, this supports direct fetal-risk assessment for selected single-gene conditions. In oncology, it supports low-frequency variant detection and longitudinal tumor-burden measurement.

The company is primarily paid when it delivers a billable molecular test result. Revenue therefore reflects three linked variables: test volume, the average selling price collected per test, and the mix of prenatal, oncology and other services. More than 90% of FY2025 revenue came from government and commercial third-party payors, making coverage, coding, claims processing and cash collection as important as the laboratory science itself.

Which revenue stream matters most?

Prenatal remains the economic engine. In Q1 2026, prenatal clinical testing revenue was $96.5 million, oncology clinical testing revenue was $10.7 million and clinical-trial support plus other services contributed $1.1 million. That means prenatal represented about 89.0% of the $108.4 million quarterly total, oncology about 9.9% and other services about 1.0%.

Why can revenue grow faster than test volume?

The model has a reimbursement lever. Q1 2026 tests delivered increased 44% year over year, while total revenue increased 84%, because overall ASP rose 28% to $571. Contracting with additional payors, improving claim acceptance, adding reimbursable applications and changing product mix can lift revenue per delivered test. The reverse is also true: reimbursement pressure or unfavorable mix can weaken revenue even when laboratory volume expands.

The latest reported period is the quarter ended March 31, 2026. BillionToOne’s Q1 2026 earnings release and Form 10-Q show a company crossing from rapid-growth diagnostics into GAAP operating profitability.

What changed year over year?

What does management expect for FY2026?

After Q1, management raised FY2026 revenue guidance to $450 million-$465 million, implying 48%-52% growth over FY2025 revenue of $305.1 million. The key analytical question is not simply whether revenue reaches the range, but whether a business investing heavily in new assays can maintain gross margin and operating profitability near current levels while oncology becomes a larger share.

BillionToOne’s history is short, but several decisions explain the current revenue concentration, platform story and governance structure. The most useful history is therefore a sequence of commercial and scientific transitions rather than a founder biography.

1. 2016
   BillionToOne was founded around the idea that synthetic counting references could enable accurate molecular quantification at very low signal levels.
2. 2019
   The company received its first commercial sample and launched Unity, converting an R&D platform into a clinical laboratory business.
3. 2020
   Aneuploidy and RhD applications were added to form Unity Complete, expanding the prenatal value proposition beyond a single use case.
4. 2023
   Northstar Select and Northstar Response launched, extending the same molecular-counting platform into oncology therapy selection and monitoring.
5. 2025
   Northstar Select received MolDX coverage for eligible advanced solid-tumor patients; FY2025 revenue reached $305.1M and 610,000 tests were delivered.
6. November 2025
   The IPO produced approximately $286.9M of net proceeds and introduced the dual-class public-company structure.
7. 2026
   The company launched oncology add-ons and Unity Confirm, while continuing work on a tissue-free pan-cancer minimal residual disease test.

What did the oncology move change?

Prenatal testing gave BillionToOne a high-volume commercial base, reimbursement infrastructure and laboratory scale. Oncology introduced a larger potential market and repeat-testing logic, but also a different customer set, stronger incumbents, more demanding clinical-evidence requirements and initially lower test-level margins. The strategic trade-off is clear: oncology could diversify growth and increase longitudinal testing, but it also raises execution, reimbursement and evidence-generation risk.

What is technically differentiated?

The company’s QCT-based smNGS platform is designed to count original target molecules rather than rely only on relative sequencing read frequencies. In oncology, Northstar Select reports a 0.15% limit of detection for selected alterations, while Northstar Response reports detection down to a 0.01% tumor fraction and measures more than 2,200 cancer-specific methylation loci. The official Northstar product platform positions this sensitivity as useful for finding actionable variants and detecting treatment response earlier than imaging in some settings.

Which non-technical resources reinforce the moat?

By December 31, 2025, the company had processed more than one million smNGS-based tests, employed 713 people and had 125 employees in R&D. Scale produces several resources that a VRIO-style analysis would flag: proprietary assay designs, growing molecular datasets, reimbursement know-how, direct specialist sales teams and integrated software for ordering, billing and reporting. These resources are valuable, but their durability depends on patents remaining enforceable and on competitors failing to replicate the clinical outcome.

Who are the main competitors?

The competitive advantage is therefore conditional. Analytical performance can open the door, but durable economics require clinical evidence, guideline inclusion, payer contracts, reliable turnaround times and a provider experience that lowers switching incentives.

Why is ASP the most important commercial KPI?

Overall ASP is the weighted average revenue from prenatal and oncology tests divided by delivered and billable tests. It increased from $445 in Q1 2025 to $561 in Q4 2025 and $571 in Q1 2026. The progression captures improved in-network contracting, reimbursement operations and product mix. Because the laboratory has meaningful fixed personnel and facility costs, an additional dollar of ASP can carry attractive incremental margin once the test is already being processed.

What could interrupt margin expansion?

The company reported Q1 2026 overall cost of goods sold per test of $153. Oncology tests currently have higher costs per test and lower margins because volumes are smaller and reimbursement is less mature. A faster oncology mix shift could therefore pressure consolidated unit cost even when each assay is improving. Payer denials, coding changes, recoupments and long collection cycles can also change recognized revenue or cash conversion after the laboratory work is complete.

The 2025 Form 10-K makes reimbursement risk explicit: third-party payors represented more than 90% of FY2025 and FY2024 revenue, and international markets contributed less than 1% of FY2025 revenue. This is a high-growth U.S. reimbursement model, not yet a geographically diversified diagnostics franchise.

The November 2025 IPO materially changed the balance sheet. As of March 31, 2026, cash and cash equivalents were $537.5 million and working capital was $567.0 million. The company also had $90.0 million of term-loan principal outstanding, leaving substantial liquidity after debt.

Is the company generating cash?

What does the balance sheet permit?

Liquidity allows BillionToOne to fund clinical studies, assay development, payer evidence and specialist sales expansion without relying on near-term external equity. It also creates room for acquisitions, although management has not established a recurring acquisition pattern. The main caution is that one profitable quarter does not erase the accumulated deficit or the possibility that rapid hiring, launch costs and reimbursement delays could reduce future cash generation.

Economic ownership and voting control are not the same. Class A shares carry one vote each, while Class B shares carry 15 votes each. The founders held all disclosed Class B shares as of the 2026 proxy date, concentrating voting power despite owning a smaller percentage of total economic shares.

What does the proxy reveal?

The 2026 proxy statement also shows a seven-member board, with five directors classified as independent under Nasdaq rules, a lead independent director and staggered three-year terms. This provides formal oversight, but the combined founder voting position means public shareholders have limited ability to force a strategic change without founder support.

BillionToOne’s opportunity set is unusually broad for a company whose revenue is still concentrated in one franchise. The same fact creates risk: management must convert multiple scientific programs into evidence-backed, reimbursed products without losing commercial discipline.

Which risks are most material?

A student applying Porter’s Five Forces would see high rivalry, powerful payors, meaningful evidence-based barriers to entry and a persistent substitute threat from incumbent laboratory methods or imaging. A PESTLE reading would emphasize reimbursement policy, laboratory regulation, genetic-data privacy and the pace of clinical guideline change. These frameworks point to the same conclusion: scientific sensitivity is necessary, but payer acceptance and clinical workflow adoption determine economic value.

A DCF for BillionToOne should not extrapolate Q1 2026 growth mechanically. The company is emerging from a small base, and quarterly revenue reflects both volume and rapidly improving reimbursement. The central task is to separate sustainable adoption from temporary ASP catch-up, then model the cost of building oncology and new prenatal applications.

Which operating assumptions drive intrinsic value?

The annual baseline is also important. In FY2025, revenue doubled to $305.1 million, gross margin reached 68%, operating income was $16.0 million and net income available to common shareholders was $2.9 million. The FY2025 results also show 610,000 delivered tests and a $495 overall ASP. Those full-year figures provide a more stable base than one quarter, while Q1 2026 shows the latest direction.